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Background: The new tuberculosis (TB) treatment in Tanzania contains rifampicin for six 
months. Direct observation of drug intake at the health facility for this period is not feasible.
Methods: Patients and health staff in three districts were interviewed to assess the burden 
of the current treatment strategy, and opinions on a proposed new strategy where patients are 
able to choose the place of treatment and the treatment supervisor, and receive treatment as a 
daily combination tablet.
Results: The study included 343 patients in 42 facilities. Daily collection of drugs was perceived 
as burdensome irrespective of distance needed to travel. Eighty percent of patients viewed 
medication taken at home or at a closer health facility as an improvement in TB-services. The 
proposed new treatment strategy was rated favorably by 85% of patients and 75% of health staff. 
Fifty-three percent of patients would opt for home-based treatment, and 75% would choose a 
family member or the spouse as treatment supporter.
Conclusion: Home-based supervision of TB treatment with fewer drugs is an expressed pref-
erence of TB patients in Tanzania. Such a strategy is now being assessed in a pilot study. If 
effective and feasible, the strategy will contribute to an improved TB control strategy.
Introduction
Tuberculosis (TB) is one of the leading causes of death in the United Republic of 
Tanzania (WHO 2006a). The case load of TB (all forms) in Tanzania was 39,847 in 
1995 and increased to 64,200 in 2005 (WHO 2007). This increase is largely attributed 
to the ongoing HIV-epidemic in the country. Currently, the World Health Organization 
(WHO) estimates the incidence of TB (all forms) to be 342 per 100,000 population 
(WHO 2007). The estimated prevalence of HIV in the adult population (15–49 years) 
is 7% (TACAIDS et al 2005). The cornerstone of TB control is Directly Observed 
Therapy Short course (DOTS), which comprises of diagnosis by sputum microscopy 
and therapy with a 6–8 months drug regimen (WHO 2003). With rifampicin being 
part of the drug regimen during the initial two months (the intensive phase), it is 
recommended that the taking of treatment is observed to prevent selection of rifam-
picin-resistant strains of Mycobacterium Tuberculosis due to nonadherence. After this 
time, in the continuation phase, the regimen does, in general, not include rifampicin 
and treatment is collected on a monthly basis and taken by the patient unsupervised. 
Conventionally, following recommendations of the WHO and the International 
Union against Tuberculosis and Lung Disease, observation of drug intake is done at 
the treatment center by health staff (WHO 2003). This implies that the patient has to 
report each day to the facility and that health staff has to attend daily to these patients 
in addition to other duties.Patient Preferences and Adherence 2008:2 2
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In 2006, the initial drug regimen for new TB patients 
in Tanzania was changed to include rifampicin also in the 
continuation phase because studies suggested that such a 
regimen was more effective in situations with a high prevalence 
of HIV-infection like in Tanzania (Johnson et al 1997; El-Sadr 
et al 2001; Korenromp et al 2003). This new regimen asks for a 
strict adherence, preferably by direct observation of drug intake. 
Having patient coming to a treatment facility and staff attending 
to them on a daily basis for 6 months puts an enormous stress 
on both sides and its feasibility is questionable.
It was therefore pertinent for the National Tuberculosis 
and Leprosy Programme (NTLP) of Tanzania to rethink its 
strategy of allocating and supervising TB treatment. The new 
strategy should be able to maintain adequate observation of 
treatment intake, should not increase the already high work 
load of health facilities, and be acceptable for the TB patients 
and the community at large.
The strategy for treatment allocation and observation 
that was designed has three components. First, all identiﬁ  ed 
TB patients will be given the choice between home-based 
treatment supervision and health facility-based supervision. 
Second, patients who opt for home-based supervision can 
identify their own treatment supporter. Third, all four drugs 
of the intensive phase will be given as a single ﬁ  xed-dose 
combination tablet (4FDC).
To assess whether such a strategy was acceptable for TB 
patients and health staff, the NTLP conducted an assessment 
in three representative districts in Tanzania. Both patients 
and health staff were interviewed to ascertain their views on 
the current DOTS strategy, their suggestions for improving 
their TB treatment, and their opinion on the proposed new 
strategy. The current manuscript describes the outcomes of 
this assessment.
Methods
The study was carried out in three geographically representa-
tive districts of Tanzania in 2004. Two rural districts were 
selected (Korogwe and Mbarali), and one urban district 
(Nyamagana). The study districts were chosen for conve-
nience based on being representative for a rural setting an 
urban setting. Within the districts there was no sampling 
but all TB treatment centres (42) were included. Within the 
centres, all the patients who were on treatment were included 
as well as the attending health staff. The health staff included 
clinical ofﬁ  cers, nurses/dispensers, attendants, and TB-coor-
dinators. Three study teams of trained researchers who were 
assisted by local TB-coordinators known in the area carried 
out semi-structured interviews.
The questionnaires were designed in close collaboration 
with all stakeholders involved to assure that the questions 
were relevant and feasible. It was piloted in a sample of 
TB patients in Dar es Salaam, Tanzania. Unclear questions 
were rephrased. The narrative accounts of the interviewees 
were translated and analysed using qualitative software 
(MAX QDA). For most questions, multiple answers 
were possible. All data were entered in a central database 
at Ifakara centre, Tanzania. Different responses to the 
questions were tallied. No formal statistical analyses were 
performed.
Ethical approval for the study was obtained from the 
Institutional Review Board of the National Institute for 
Medical Research. All participants provided verbal consent 
to participate in the study.
Results
All 42 health facilities agreed to participate, as well all reg-
istered patients and health staff in the facilities. The study 
included all 343 patients who were receiving TB treatment at 
the health facilities, and 90 health care workers. Two hundred 
patients (58%) were in the intensive phase and 143 (42%) 
in the continuation phase of anti-TB treatment. At the time 
of the study, patients on the intensive phase reported to the 
health facility daily for DOT, while those on the continuation 
phase collected their drugs once a month. Of the health care 
workers, 41 (46%) were senior (Regional or District TB and 
Leprosy Coordinator [R/DTLC] or Clinical Ofﬁ  cer [CO]), 
and 49 (54%) were junior (nurse or dispenser). Not all patients 
answered all the questions because the semi-structured nature 
of the questionnaire gave this opportunity.
Appraisal of the current health 
facility-based DOT system
Of the 200 patients who collected their medication daily, 
164 (82%) lived within 5 kilometres of the health facility, 
and 36 (18%) lived more than 5 kilometres away from the 
nearest health facility. In the only urban district 99% of 
the patients in the intensive phase were living within 5 
kilometres from the nearest health facility. The common 
mode of transport to the health facility was by walking, 
and by bus or car.
Information on the appraisal of the current health facil-
ity-based DOT strategy was obtained from 193 (97%) of 
the patient in the intensive phase. The daily travel to the 
health facility was seen as a burden by 58% of the patients 
living within 5 kilometres of the health facility, and 72% of 
the patient living further way. Reasons for this burden were Patient Preferences and Adherence 2008:2 3
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the distance, the generally poor health of the patients, and 
problems in ﬁ  nding or ﬁ  nancing transport (Table 1).
Reasons for not ﬁ  nding the daily travel to the health 
facility a burden were close distance, the possibility of 
transport, the wish to be cured, and the responsibility felt 
towards the health worker. Most health worker shared the 
view of the patients that daily DOT at the health facility is 
a burden for the patient.
“Because my body hurts I have no strength. I get very tired 
when I walk, although I am living nearby. I take a long 
time to reach the center. As you can see, my condition is 
not good.”
(35-year-old male)
Suggestions to improve the current TB 
treatment
Patients and staff were invited to give unsolicited suggestions 
for improving their TB treatment. This was done by 140 (70%) 
of the patients in the intensive phase and 91 (64%) of the 
patients in the continuation phase (Table 2). Three quarters 
of the patients saw the possibility of taking drugs at home or 
at the smaller but closer dispensaries as a major improvement 
to the current system. Other improvements could be made by 
improving the health services in general, and a shorter dura-
tion of treatment or fewer drugs. Suggestions for improvement 
to the system speciﬁ  cally made by health care workers were 
the involvement of communities and relatives in the treatment, 
Table 1 Appraisal of the current DOT strategy
 Patients*    Health  workers 
  5 km  5 km  CO/RTLC  Nurse
 N  = 161  N = 32  N = 41  N = 49
HF-DOT is a burden  93 (57.8)  23 (71.9)  32 (78.0)  31 (63.3)
Daily walk difﬁ  cult  37 (39.8)  5 (21.7)  16 (47.1)  21 (63.6)
Long distance to HF  66 (71.0)  17 (73.9)  26 (76.5)  27 (81.8)
Weakness/poor health  49 (52.7)  6 (26.1)  16 (47.1)  15 (45.5)
Too much pain  28 (30.1)  4 (17.4)   
Financial/Transport problems  17 (18.3)  8 (34.8)  13 (38.2)  6 (18.2)
No child care  3 (3.2)  4 (17.4)   
HF-DOT is not a burden  68 (42.2)  9 (71.9)  7 (17.1)  14 (28.6)
Live close to HF  39 (60.9)  1 (10)   
Want to be cured  17 (26.6)     
No transport problems  8 (12.5)  6 (60)   
Important to see health worker  7 (10.9)  1 (10)   
Feel responsible  7 (10.9)  1 (10)   
Other      
Notes: *in the intensive phase of treatment (daily drug collection); All numbers are n (%).
Table 2 Suggestions for simplifying treatment
 Patients      Health  Workers 
 All  Intensive    Continuation  CO/RTLC  Nurse
   phase  phase
 N  = 231  N = 140  N = 91  N = 41  N = 50
Provide treatment at home  115 (49.6)  79 (56.4)  36 (39.6)  13 (31.7)  16 (32.0)
Provide treatment closer to home  65 (28.1)  31 (22.1)  34 (37.4)  11 (26.8)  17 (34.0)
Improve services  54 (23.4)  29 (20.7)  25 (27.5)  10 (24.4)  5 (10.0)
Shorten treatment/fewer drugs  27 (11.7)  21 (15.0)  6 (6.6)  12 (29.3)  14 (28.0)
More HF providing diagnostics  23 (10.0)  8 (5.7)  15 (16.5)  11 (26.8)  8 (16.0)
Involve relatives/communities        12 (29.3)  11 (22.0)
Health education        6 (14.6)  7 (14.0)
Improve transport  16 (6.9)  11 (7.9)  5 (5.5)  5 (12.2)  4 (8.0)
No change needed        2 (4.9)  2 (4.0)
Notes: All numbers are n (%).Patient Preferences and Adherence 2008:2 4
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and the provision of health education. Four health workers did 
not see a reason to change the current DOT system.
“If we could be given monthly drugs and have them from 
home, it would help reduce transport costs. It will also help 
us patients to complete the dose because even when we 
do not have money for transport, we will have the drugs 
at home. The family will have money for its expenditure 
because the money, which was being used as a bus fare, 
will now be used for the family.”
(31-year-old female)
Views on patient-centred treatment (PCT)
The patients were thoroughly explained that PCT consisted 
of having the opportunity to choose where and by whom their 
TB treatment was supervised. It was also made clear that 
regular returns to the health facility for check-up, sputum 
examinations, and drug collection were still needed, and 
that with home-based supervision a good record keeping 
had to be performed. To ensure that the concept was under-
stood well, the patients had to explain the system back to 
the interviewer.
Patient-centred treatment was considered ‘very good’ or 
‘good’ by 79% of the patients, 86% of the COs and RTLCs, 
and 76% of the nurses (Table 3). PCT was rated as not good 
by 10% of the patients, 7% of the COs and RTLCs, and 14% 
of the nurses.
Most of the patients and all but one health care workers 
gave reasons for their rating of PCT (Table 3). Reasons 
for a positive attitude of patients towards PCT included 
that it would reduce the tiresome daily travel, that there 
was more time to rest, and that it would make treatment 
more convenient. Health workers gave similar reasons 
for a positive attitude toward PCT, but included also the 
possible reduction of overcrowding and workload at the 
health facilities.
“We like the approach very much. It will help us to get 
more rest, less fare, and it will make us get time to sleep 
after swallowing drugs.”
(40-year-old male)
Reasons for a negative attitude of patients toward PCT 
included the notion that home treatment in general was not 
preferred due to lack of expertise, the opinion that observa-
tion of treatment in a health facility would be more reliable, 
and the believe that home-based treatment would lead to 
nonadherence (Table 3). Health workers reported a wide 
range of possible disadvantages of PCT of which the main 
were the difﬁ  culty in managing the strategy, the fear that an 
inappropriate supporter would be chosen, nonadherence, and 
improper storage of drugs.
“The supporter may fail to understand how to give drugs 
to the patient. Also he may not understand the side effects 
of the drug. So the home-centred strategy is not good. At 
the hospital there is good supervision hence it is good for 
the patient to take the drugs in health facilities.” (Clinical 
Ofﬁ  cer male)
Place of supervision and type of supporter
A small majority (53%) of both patients in the intensive phase 
and in the continuation phase would opt for home-based 
DOT when they had a choice (Table 4). This choice was not 
inﬂ  uenced by sex, age, marital status, or level of education. 
Even a considerable proportion of patients living within 
5 kilometres of the health facility would choose home-based 
DOT if given a choice.
Reasons of patients to choose for home-based DOT 
included the treatment being less disruptive to their lives, time 
to rest, less costs, and the opportunity to keep working. A choice 
for health-facility based DOT was made because of the notion 
that treatment would be better, it was more convenient, and the 
believe that home-based treatment was in general not good.
Table 3 Views on patient centered treatment
 Patients  Health  workers
   CO/RTLC  nurse
 N  = 343  N = 42  N = 50
Very good/Good  271 (79.0)  36 (85.7)  38 (76.0)
No daily walking  124 (51.2)  14 (38.9)  16 (53.3)
Time to rest  82 (33.9)  9 (25.0)  9 (24.3)
Freedom to choose  59 (24.4)  13 (11.1)  13 (10.8)
Convenient/less disruption  52 (21.5)  21 (58.3)  21 (56.8)
Reduced costs  24 (9.9)  4 (11.1)  1 (2.7)
Reduces defaulters    1 (2.8)  3 (8.1)
Reduces stigma    4 (11.1) 
Reduces workload/overcrowding    2 (5.6)  5 (13.5)
No further explanation given  29 (10.7)    1 (1.1)
Neutral (OK)  28 (8.2)  3 (7.1)  5 (10.0)
Not good  33 (9.6)  3 (7.1)  7 (14)
Home treatment not good  18 (62.1)   
Supervision at HF more reliable  17 (58.6)   
Difﬁ  cult to manage strategy    21 (51.2)  20 (40.0)
Inadequate supporter chosen    26 (63.4)  23 (46.0)
Difﬁ  cult to adhere to intake  5 (17.2)  26 (63.4)  25 (50.0)
Misuse of drugs    4 (9.8)  3 (6.0)
Storage problems    9 (22.0)  12 (24.0)
Risk of resistance    5 (12.2)  4 (8.0)
No further explanation given  4 (12.1)  1 (2.4) 
Don’t know  11 (3.2)   
Notes: All numbers are n (%).Patient Preferences and Adherence 2008:2 5
Patient preferences for TB treatment
“As a businessman, instead of going to the health facility 
to collect drugs, I will be able to continue with my 
business.”
(30-year-old male)
The type of supporter for home-based DOT would be 
for the large majority of patients (74%) either a spouse or a 
family member (Table 4). This did not differ not much by sex 
of the patient. Divorced men would opt for a family member, 
while this was less outspoken for divorced women. From 
the interviews it became clear that the choice for treatment 
supporter was driven by a close relationship, feelings of trust 
and helpful experiences in the past.
“I would choose my younger brother because he is the 
one who brings me to the hospital when I am sick and he 
loves helping me. When I am tired he may come to collect 
drugs for me.”
(32-year-old male)
The main role for supporters according to the patients 
would be to collect drugs, to encourage the drug taking, and 
to prepare food. Other tasks mentioned were the provision 
of support, to give feedback to the health worker, and help 
in the household.
Views on home-based drug taking
Patients who would choose home-based DOT did not see 
major problems in taking their daily medication and were 
aware of the need of a good compliance. From the point 
of both the patients and the health staff, proof a regular 
drug intake should be trough a formal conﬁ  rmation by the 
supporter, a visible improvement in patient’s health, or 
submission of empty packs or ﬁ  lled records on patient’s 
treatment card.
“I will be ticking my treatment cards. My wife will conﬁ  rm 
this. I will accompany my supporter often to the health 




The current study showed that daily contact with a health 
facility to obtain TB treatment was seen as a burden by both 
the patients and the health staff. Fifty percent of the patients 
who found daily travel to the health facility a burden lived 
within 5 kilometres of the facility. It is therefore not surpris-
ing that patients mentioned the possibility to take their drugs 
at a nearer health facility or at home as a way to improve the 
current strategy of TB treatment delivery. This is in addition 
to the expressed wish of having fewer drugs and/or a shorter 
treatment period. These factors were also mentioned by the 
health workers as the most important factors for improvement 
the current TB treatment strategy.
Both patients and health workers had a positive attitude 
towards a strategy where the patients would be able to make 
the choice of the place of supervision and the supervisor. 
A large majority of patients, who would opt for home-based 
supervision, would opt for their spouse or a family member 
as their treatment supporter.
Studies in Nepal (Newell et al 2006), Swaziland (Wright 
et al 2004), Kenya (Kangangi et al 2003), Uganda (Adatu 
et al 2003), Malawi (Manders et al 2001), and Thailand 
(Akkslip et al 1999) showed that supervision of TB-treatment 
can be done outside the health facility without compromis-
ing treatment success rates. The study in Nepal reported that 
supervision at home by either a community health worker 
or a family member resulted in a proportion of successful 
treatment outcomes that was in line with the targets set by 
WHO (Newell et al 2006).
Within the TB-community, the discussion continues 
whether family members are suitable to supervise treatment. 
In a reaction to the publication of the Nepal study, Garner et al 
supported the use of family members as treatment supporters 
(Garner and Volmink 2006). They see the fact as whether 
these family members do actually observe treatment intake 
as immaterial. It is the communication between patient, 
supporter, and health staff, and the sharing of responsibility 
for treatment adherence that makes the intervention in Nepal 
successful according to the authors. On the other side of the 
debate, Frieden and Sbarbaro (2006) stated that TB patients in 
many countries have received suboptimal treatment because 
of the use of family members as treatment supporters. This 
statement is underscored by a study in the southern parts of 
Thailand, where 35% of the family members who acted as 
Table 4 Choice of DOT and type of treatment supporter
 All  patients  Male  Female
 N  = 343  N = 206  N = 137
Preferred place of DOT     
Home  182 (53.1)  111 (53.9)  71 (51.8)
Health facility  161 (46.9)  95 (46.1)  66 (48.2)
Supporter at home     
Spouse  51 (28.0)  36 (32.4)  15 (21.1)
Family member  83 (45.6)  49 (44.1)  34 (47.9)
Self  18 (9.9)  10 (9.0)  8 (11.3)
Health worker  12 (6.6)  6 (5.4)  6 8.5)
Other  18 (9.9)  10 (9.0)  8 (11.3)
Notes: All numbeSrs are n (%).Patient Preferences and Adherence 2008:2 6
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treatment supporter acknowledge not to consistently observe 
treatment intake by the patient, in comparison to 11% of the 
health staff at health facilities (Pungrassami et al 2002).
A large community randomized trial in South Africa 
showed that 59% of the TB patients who could choose their 
treatment supporter would opt for a family member (Thiam 
et al 2007). The remaining 41% chose either a health care 
worker at the health facility or within the community. Of 
the patients supervised by family members, 4% defaulted 
treatment compared to 8% of the patients supervised by 
health staff. Treatment success was achieved in 88% of the 
patients supervised by family members compared to 77% of 
the patients supervised by health staff.
Whether family members can be treatment supporters will 
not only depend on rates of default and treatment success, 
but also on cultural circumstances (Macq et al 2003). In 
a home-based treatment supervision study in Uganda, the 
treatment supervision was preferably done by a neighbour 
rather than a family member (Adatu et al 2003). This was 
to avoid uneasiness within the family if the relationship 
between patient and supporter was not congruent with 
hierarchical pattern commonly seen in Ugandan families. 
This example makes it clear that treatment delivery strategies 
and supervision strategies are context-speciﬁ  c and that the 
strategies have to be carefully assessed in each new setting.
The National Tuberculosis and Leprosy Programme of 
Tanzania is currently conducting a pilot study to asses the efﬁ  cacy 
of the proposed new treatment allocation and supervision strategy 
in three districts other than those involved in the assessment of 
needs. The proposed strategy can be seen as patient-centered 
since it is the patient who decides on where and how of treatment 
supervision. Such a patient-centered approach ﬁ  ts within the 
universal TB-control as described in the Stop-TB strategy 
(2006b). This strategy focuses on DOTS expansion, addressing 
TB/HIV and multidrug-resistent TB, strengthening of health 
systems, engaging of all health care providers, empowerment 
of TB patients and communities, and enabling research. We 
realize that the empowerment of TB-patients and communities is 
far wider than home-based treatment and supervision by family 
members. However, the freedom of choice to the patients gives 
them more ownership of their own treatment and engages the 
patient in taking responsibility for their treatment. Both these 
factors can contribute to improving adherence to TB-treatment 
which is essential for treatment success.
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